Attendee search 

RemoteA Ltd offers easy-to-use and cost-efficient solutions for simplifying the diagnosis of common medical disorders like cardiac arrhythmias, sleep apnea and hypertension.

Firstly, our browser-based system with state-of-the-art data security enables medical specialist consultation in the first point of care. Health care costs will be substantially reduced as fewer patients will be referred to hospitals; instead they can be diagnosed and treated in the first point of care. Simultaneously, accessibility to care and quality of care are improved.

Secondly, our smart ECG solution enables cardiac arrhythmias testing at home analogically to how blood pressure measurements were shifted from doctors' offices to homes in 1980’s and 1990’s.

Technology is based on the development since 2002.

My company Bertil Allard Holding have interest some companies in Life Science. The major investment is in Hörsam ( www.horsam.se ) but I am also a boardmember of Phoniro ( www.phoniro.se ). I have also involvment in Puls ( www.pulsinvest.se ) and the very new Brorsson Innovation ( wwww.brorssoninnovation.se ). My former company, today owned by my youngest son was Camp Scandinavia www.camp.se My main area of interest in Life Science relates to rehabilitation but in a wide aspect.

UK Trade and Investment offers free support and independent advice to Nordic companies looking to invest or locate in the UK.

The UK is home to the National Health Service (NHS) - the world’s largest publicly funded healthcare system, a hub for the development and delivery of new medicines and technologies and a proven research partner. The NHS provides access to a diverse patient population, eminent clinicians and first-class medical researchers, across the whole healthcare spectrum.

The UK is investing hundreds of millions pounds in new medical technology innovation and has a new access schemes which will put new technologies in NHS hospitals more quickly than ever before.

Meet with Mark Campbell, Associate Director, Medical Technology Evaluation Program, National Institute for Health and Clinical Excellence, UK

We offer impartial advice on where and how to set up a business in the UK,

• in-depth, tailored information, including advice on financing, recruitment and activities such as R&D, tax, human capital,

Assistance, via our Partnership Programme, in finding new partners and expanding your business,

• practical help in the field, including visits to suitable locations, finding business partners and accessing financial incentives,

We are one of the largest independent venture investors in northern Europe managing approx. 1 billion USD. Sunstone Capital Life Science Ventures focus on drugs, diagnostics and medical devices, and we use our extensive industrial experience to guide our decisions and help our portfolio companies in their development.

Unisensor is seeking investors for the development, clinical evaluation and launch of a new instrument for antibiotic susceptibility testing.

Sepsis (blood poisoning) is a serious medical condition that in US alone kills more than 100,000 annually, surpassing the number of deaths from acute myocardial infarction (AMI), stroke, or cancer. Once detected, it is paramount to initiate the proper antibiotic therapy as soon as possible, since survival chance decrease by the hour. In addition septicaemia patients is a substantial economic burden to the hospital – according to one source up to 50.000 USD per patient. Traditional AST typically takes from 15-30 hours, and Unisensor has shown that this can be decreased to less than one hour by using our patented technology. This will not only increase the survival chance and reduce the costs, but also have the societal benefit, that the emergence of multi-resistant bacteria is reduced due to the earlier usage of the proper narrow-band antibiotic therapy.

To finance the instrument development, clinical evaluation and initial sales and marketing activities Unisensor is seeking investors to enter into a joint venture or or other financial collaboration or partnership.

We are one of the largest independent venture investors in northern Europe managing approx. 1 billion USD. Sunstone Capital Life Science Ventures focus on drugs, diagnostics and medical devices, and we use our extensive industrial experience to guide our decisions and help our portfolio companies in their development.